Contribution of Next-generation Sequencing in a Case of Metastatic Breast Carcinoma with Pulmonary Lesions
- *Corresponding Author:
- Dr. Eric Dansin
Department of General Oncology
Oscar PBC Lmbret three Kbmle 59020 Lille, France
Tel: +33 320295920
Fax: +33 320295963
E-mail: [email protected]
Received date: Mar 18, 2016; Accepted date: Apr 27, 2016; Published date: May 06, 2016
Citation: Kotecki N, Escande F, Surmei-Pintilie E, Abramovici O, Bonneterre J, et al. (2016) Contribution of Next-generation Sequencing in a Case of Metastatic Breast Carcinoma with Pulmonary Lesions. J Lung Cancer Diagn Treat 1:103. doi:10.4172/jlcdt.1000103
Copyright: © 2016 Kotecki N et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Next-Generation Sequencing (NGS) provide specific cancer-related gene-sequence information which can be helpful for diagnosis and clinical decision. Here we describe the case of a patient diagnosed with HER2 positive metastatic breast cancer and successive pulmonary lesions. Despite large immunohistochemical assays. It was not possible to distinguish on first thoracic specimen between primary lung adenocarcinoma and metastasis from breast carcinoma. NGS analysis on second thoracic sample detected somatic mutations in PiK3CA and TP53 genes. This mutation profile was identical to the previously resected adenocarcinoma. NGS contribute to diagnose metachronous primary lung carcinoma and to propose a thoracic treatment in addition to systemic management of metastatic breast carcinoma. Our case report emphasizes the usefulness of NGS to guide diagnosis and treatment in the objective of precision medicine.